The pharmaceutical segment encompasses the research, development, manufacturing, and commercialization of innovative medicines across multiple therapeutic areas. This includes Rayaldee for secondary hyperparathyroidism, NGENLA for pediatric growth hormone deficiency, and a pipeline of novel therapies such as OPK88003 for type 2 diabetes and associated obesity. Research and development efforts focus on longer-acting proprietary versions of already approved therapeutic proteins and new chemical entities. The segment operates pharmaceutical platforms in various countries, including Ireland, Chile, Spain, and Mexico, and engages in global pharmaceutical research and development operations. The goal is to address unmet medical needs and improve patient outcomes through innovative pharmaceutical solutions.

The diagnostics segment, primarily through BioReference Laboratories, provides comprehensive laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases. This includes esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. The segment serves a diverse range of clients, including physician offices, clinics, hospitals, employers, and governmental units. A key focus is on developing and commercializing novel diagnostic tools, such as the 4Kscore prostate cancer testing service and point-of-care blood testing systems. The segment aims to improve patient care through accurate and timely diagnostic information, enabling better clinical decision-making and personalized treatment strategies. Strategic collaborations and partnerships enhance the segment's capabilities and market reach.